Impact of treatment response with adalimumab on risk of serious infections in patients with crohn ’s disease: secondary analysis of the pyramid registry
Treatment efficacy and safety are primary factors in choosing therapies in patients with Crohn ’s disease (CD). However, they can be perceived to be at odds with each other with more potent therapies associated with increased risk of infections. We evaluated the impact of treatment response on the risk of serious infections in adalimumab-treated patients with CD through secondary analysis o f the PYRAMID registry. (Source: Gastroenterology)
Source: Gastroenterology - January 25, 2024 Category: Gastroenterology Authors: Dhruv Ahuja, Jiyu Luo, Yuchen Qi, Gaurav Syal, Brigid Boland, John Chang, Christopher Ma, Vipul Jairath, Ronghui Xu, Siddharth Singh Source Type: research
Real-world rate and magnitude of dose escalation with biologics in patients with ulcerative colitis
The objective of this study was to assess the rate and magnitude of dose escalation with biologics in treatment of UC. (Source: Gastroenterology)
Source: Gastroenterology - January 25, 2024 Category: Gastroenterology Authors: Magdaliz Gorritz, Rifat Tuly, Kainan Sun, Thomas Creveling, Richard Moses, Deborah Fisher, Nicholas Bires, Wai Man Maria Chan, Nate Johnson, Michael Hull, Wanjiku Kariuki, Navneet Upadhyay Source Type: research
Real-world rate and magnitude of dose escalation with biologics in patients with crohn ’s disease
The objective of this study was to asse ss the rate and magnitude of dose escalation with biologics in treatment of CD. (Source: Gastroenterology)
Source: Gastroenterology - January 25, 2024 Category: Gastroenterology Authors: Magdaliz Gorritz, Rifat Tuly, Kainan Sun, Thomas Creveling, Richard Moses, Deborah Fisher, Nicholas Bires, Wai Man Maria Chan, Nate Johnson, Michael Hull, Navneet Upadhyay Source Type: research
Predictors of primary non-response and drug durability for adalimumab and infliximab in pediatric inflammatory bowel disease
This study evaluates predictors of primary non-response and long-term durability in children with IBD. (Source: Gastroenterology)
Source: Gastroenterology - January 25, 2024 Category: Gastroenterology Authors: Nicole Davidson, Grant Morris, Molly Wright, Guy Brock, Brendan Boyle, Jennifer Dotson, Hilary Michel, Ross Maltz Source Type: research
Assessing the clinical impacts of immunomodulatory withdrawal from anti-tnf combination therapy in pediatric inflammtory bowel disease
Combination therapy consists of both a monoclonal antibody against tumor necrosis factor (anti-TNF) (infliximab (IFX) or adalimumab (ADA)) and an immunomodulator (IMM) (thiopurines (TP) or methotrexate (MTX)). Although combination therapy improves clinical outcomes, the IMM may be discontinued to mitigate the risk of IMM-related adverse events. However, it is unknown how de-escalation impacts clinical outcomes in children with IBD. (Source: Gastroenterology)
Source: Gastroenterology - January 25, 2024 Category: Gastroenterology Authors: Nicholas Iovino, Brendan Boyle, Madeline McClinchie, Mahmoud Abdel-Rasoul, Jennifer Dotson, Hilary Michel, Ross Maltz Source Type: research
Real-world treatment persistence among advanced therapy-experienced patients with ulcerative colitis initiated on ustekinumab or adalimumab
This study compared persistence among ADT-experienced patients with UC initiated on ustekinumab (anti-interleukin 12/23 antibody), or adalimumab (anti-tumor necrosis factor biologic). (Source: Gastroenterology)
Source: Gastroenterology - January 25, 2024 Category: Gastroenterology Authors: Maryia Zhdanava, Sumesh Kachroo, Porpong Boonmak, Sabree Burbage, Aditi Shah, Jill Korsiak, Patrick Lefebvre, Caroline Kerner, Dominic Pilon Source Type: research
Persistence while on labeled maintenance dose among advanced therapy-na Ïve patients with ulcerative colitis initiated on ustekinumab or adalimumab
This study compared treatment persistence while on labeled maintenance dose among advanced therapy (ADT)-na ïve patients with UC on ustekinumab or adalimumab. (Source: Gastroenterology)
Source: Gastroenterology - January 25, 2024 Category: Gastroenterology Authors: Sumesh Kachroo, Maryia Zhdanava, Sabree Burbage, Porpong Boonmak, Aditi Shah, Jill Korsiak, Patrick Lefebvre, Caroline Kerner, Dominic Pilon Source Type: research
Disproportional signal of pericarditis with biological diseasemodifying antirheumatic drugs (bDMARDs) in patients with ankylosing spondylitis: a disproportionality analysis in the FAERS database
Conclusion: More reports of pericarditis were detected with AS patients on bDMARDs than with other drugs in the overall database. Further studies are warranted to investigate the underlying mechanisms and identify patient-related susceptibility factors, thus supporting timely diagnosis and safe(r) prescribing of bDMARDs. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - January 25, 2024 Category: Drugs & Pharmacology Source Type: research
Efficacy of adalimumab combined with Tripterygium wilfordii Hook F in the treatment of patient with rheumatoid arthritis: A multicenter, open ‐label, randomized‐controlled trial
ConclusionsThere were no significant differences in efficacy and safety between ADA combined with TwHF versus ADA combined with MTX in the treatment of RA. TwHF might be an alternative treatment for RA patients who are intolerant to MTX. (Source: International Journal of Rheumatic Diseases)
Source: International Journal of Rheumatic Diseases - January 24, 2024 Category: Rheumatology Authors: Feng Luo,
Shuo ‐Yan Gau,
Yu‐xia Wu,
Hou‐li Liao,
Fang Tang,
Qin Zhong,
Ying Huang,
Lei Hou,
Zheng‐qi Liu,
Jin‐long Cai,
Yue‐peng Cao,
Dao‐min Lu,
Yang An,
Wei‐ya Lan,
Can Liu,
Chang‐ming Chen,
Er‐tao Jia,
Xue‐ming Ya Tags: ORIGINAL ARTICLE Source Type: research
Adalimumab vs placebo as add-on to Standard Therapy for autoimmune Uveitis: Tolerability, Effectiveness and cost-effectiveness--a protocol for a randomised controlled trial (ASTUTE trial)
Introduction
Adalimumab is an effective treatment for autoimmune non-infectious uveitis (ANIU), but it is currently only funded for a minority of patients with ANIU in the UK as it is restricted by the National Institute for Health and Care Excellence guidance. Ophthalmologists believe that adalimumab may be effective in a wider range of patients. The Adalimumab vs placebo as add-on to Standard Therapy for autoimmune Uveitis: Tolerability, Effectiveness and cost-effectiveness (ASTUTE) trial will recruit patients with ANIU who do and do not meet funding criteria and will evaluate the effectiveness and cost-effectiveness of ...
Source: BMJ Open - January 24, 2024 Category: General Medicine Authors: Hazell, M., Reeves, B., Rogers, C. A., Pike, K., Culliford, L., Baos, S., Lui, M. P. Y., Beare, N. A. V., Pavesio, C., Denniston, A. K., Wordsworth, S., Keane, P. A., Wilson, R., Folkard, A., Peto, T., Sharma, S. M., Dick, A. Tags: Open access, Ophthalmology Source Type: research
Epstein-Barr virus-positive mucocutaneous ulcer in a patient with ulcerative colitis: a recently described entity to take into account
We present the case of a 31-year-old man with ulcerative proctitis being treated with azathioprine (AZA) and adalimumab (ADA), who was admitted to the hospital due to suspicion of a moderate-severe flare of ulcerative proctitis. Microbiological stool analyses were negative, with a positive fecal calprotectin test (2700 mg/kg). Rectoscopy showed severe endoscopic activity, taking multiple biopsies. Intravenous steroids were started at a dose of 60 mg/day. He presented a favorable clinical and analytical evolution, being discharged from the hospital. The histological results were received at gastroenterology consultation, be...
Source: Revista Espanola de Enfermedades Digestivas - January 23, 2024 Category: Gastroenterology Authors: Álvaro Yagüe Parada Orencio Bosch Esteva Daniel Calero Bar ón Andrea Blanco Fern ández V íctor Manuel Castellano Megías Sara Aurora Rodr íguez Vargas Source Type: research
Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor- α
IntroductionWe evaluated baseline Clearance of anti-tumor necrosis factors and human leukocyte antigen variant (HLA DQA1*05) in combination as poor prognostic factors (PPF) of pharmacokinetic (PK) origin impacting immune response (formation of antidrug antibodies) and disease control of inflammatory bowel disease (IBD) patients treated with infliximab or adalimumab.MethodsBaseline Clearance was estimated in IBD patients before starting treatment using weight and serum albumin concentrations. HLA DQA1*05 carrier status (rs2097432 A/G or G/G variant) was measured using real time polymerase chain reaction. The outcomes consis...
Source: Frontiers in Immunology - January 23, 2024 Category: Allergy & Immunology Source Type: research
Correction to: Is the Availability of Biosimilar Adalimumab Associated with Budget Saving? A Difference-in-Difference Analysis of 14 Countries
(Source: BioDrugs)
Source: BioDrugs - January 22, 2024 Category: Drugs & Pharmacology Source Type: research
Active Tuberculosis in a Patient Receiving Adalimumab for Psoriatic Arthritis and Chemoprophylaxis for Latent Tuberculosis Infection
We report a rare case of active tuberculosis despite chemoprophylaxis for LTBI in a patient receiving adalimumab for PsA. A 60-year-old Japanese woman who had received a diagnosis of psoriasis at age 35 years presented with arthralgia of the right hand, which she first noticed 2 months previously. Physical examination showed scattered erythematous papules and plaques with scales on her trunk, extremities, and scalp. Her right metacarpophalangeal and proximal interphalangeal joints were swollen and painful, and her right wrist and elbow were painful. PsA was diagnosed and adalimumab was initiated. Because an interferon-γ r...
Source: Journal of Nippon Medical School - January 21, 2024 Category: Universities & Medical Training Authors: Shun Miyazaki Kazue Fujita Saeko Ozaki Susumu Ichiyama Michiko Ito Toshihiko Hoashi Naoko Kanda Hidehisa Saeki Source Type: research